The role of cytochrome P2C19 in r-warfarin pharmacokinetics and its interaction with omeprazole

Therapeutic Drug Monitoring

Volumn 30, Issue 3, 2008, Pages 276-281

  Uno, Tsukasa ^a   Sugimoto, Katsuyoshi ^b   Sugawara, Kazunobu ^c   Tateishi, Tomonori ^b  

^a UNIVERSITY OF THE RYUKYUS   (Japan)

^b HIROSAKI UNIVERSITY   (Japan)

^c AOMORI UNIVERSITY   (Japan)

Author keywords

CYP2C19; Omeprazole; Pharmacokinetic interaction; R warfarin; S warfarin

Indexed keywords

CYTOCHROME P450 2C19; OMEPRAZOLE; PLACEBO; PROTHROMBIN; WARFARIN; ANTICOAGULANT AGENT; CYP2C19 PROTEIN, HUMAN; MIXED FUNCTION OXIDASE; PROTON PUMP INHIBITOR; UNSPECIFIC MONOOXYGENASE;

ADULT; ANTICOAGULATION; AREA UNDER THE CURVE; ARTICLE; BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG METABOLISM; ENANTIOMER; FEMALE; GENOTYPE; HALF LIFE TIME; HUMAN; INTERNATIONAL NORMALIZED RATIO; MALE; PHARMACODYNAMICS; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; PROTHROMBIN TIME; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; ALLELE; BIOTRANSFORMATION; DRUG INTERACTION; GENETICS; METABOLISM; PHENOTYPE; STEREOISOMERISM;

ADULT; ALLELES; ANTICOAGULANTS; AREA UNDER CURVE; ARYL HYDROCARBON HYDROXYLASES; BIOTRANSFORMATION; DOUBLE-BLIND METHOD; DRUG INTERACTIONS; FEMALE; GENOTYPE; HUMANS; MALE; MIXED FUNCTION OXYGENASES; OMEPRAZOLE; PHENOTYPE; PROTHROMBIN TIME; PROTON PUMP INHIBITORS; STEREOISOMERISM; WARFARIN;

EID: 47249146409     PISSN: 01634356     EISSN: 15363694     Source Type: Journal    
DOI: 10.1097/FTD.0b013e31816e2d8e     Document Type: Article

References (19)

1. Hirsh J, Dalen JE, Anderson DR, et al. Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest. 1998; 114:445S-469S.
2. Chan E, McLachlan A, O'Reilly R, et al. Stereochemical aspects of warfarin drug interactions: use of a combined pharmacokinetic-pharmacodynamic model. Clin Pharmacol Ther. 1994;56:286-294.
3. Wittkowsky AK. Drug interactions update: drugs, herbs, and oral anticoagulation. J Thromb Thrombolysis. 2001;12:67-71.
4. Holbrook AM, Pereira JA, Labiris R, et al. Systematic overview of warfarin and its drug and food interactions. Arch Intern Med. 2005;165: 1095-1106.
5. Sutfin T, Balmer K, Bostrom H, et al. Stereoselective interaction of omeprazole with warfarin in healthy men. Ther Drug Monit. 1989;11: 176-184.
6. Kaminsky LS, Zhang ZY. Human P450 metabolism of warfarin. Pharmacol Ther. 1997;73:67-74.
7. Ko JW, Sukhova N, Thacker D, et al. Evaluation of omeprazole and lansoprazole as inhibitors of cytochrome P450 isoforms. Drug Metab Dispos. 1997;25:853-862.
8. Li XQ, Andersson TB, Ahlström M, et al. Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities. Drug Metab Dispos. 2004;32:821-827.
9. Sohn DR, Kobayashi K, Chiba K, et al. Disposition kinetics and metabolism of omeprazole in extensive and poor metabolizers of Smephenytoin 4′-hydroxylation recruited from an Oriental population. J Pharmacol Exp Ther. 1992;262:1195-1202.
10. Takahashi H, Echizen H. Pharmacogenetics of warfarin elimination and its clinical implications. Clin Pharmacokinet. 2001;40:587-603.
11. De Morais SM, Wilkinson GR, Blaisdell J, et al. Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese. Mol Pharmacol. 1994;46:594-598.
12. Yasar U, Eliasson E, Dahl ML, et al. Validation of methods for CYP2C9 genotyping: frequencies of mutant alleles in a Swedish population. Biochem Biophys Res Commun. 1999;254:628-631.
13. Uno T, Niioka T, Hayakari M, et al. Simultaneous determination of warfarin enantiomers and its metabolite in human plasma by columnswitching high-performance liquid chromatography with chiral separation. Ther Drug Monit. 2007;29:333-339.
14. Shimizu M, Uno T, Niioka T, et al. Sensitive determination of omeprazole and its two main metabolites in human plasma by column-switching highperformance liquid chromatography: application to pharmacokinetic study in relation to CYP2C19 genotypes. J Chromatogr B. 2006;832: 241-248.
15. Takahashi H, Kashima T, Nomizo Y, et al. Metabolism of warfarin enantiomers in Japanese patients with heart disease having different CYP2C9 and CYP2C19 genotypes. Clin Pharmacol Ther. 1998;63: 519-528.
16. Scordo MG, Pengo V, Spina E, et al. Influence of CYP2C9 and CYP2C19 genetic polymorphisms on warfarin maintenance dose and metabolic clearance. Clin Pharmacol Ther. 2002;72:702-710.
17. Obayashi K, Nakamura K, Kawana J, et al. VKORC1 gene variations are the major contributors of variation in warfarin dose in Japanese patients. Clin Pharmacol Ther. 2006;80:169-178.
18. Unge P, Svedberg LE, Nordgren A, et al. A study of the interaction of omeprazole and warfarin in anticoagulated patients. Br J Clin Pharmacol. 1992;34:509-512.
19. Hemeryck A, Belpaire FM. Selective serotonin reuptake inhibitors and cytochrome P-450 mediated drug-drug interactions: an update. Curr Drug Metab. 2002;3:13-37.